Hemab Therapeutics is likely to gain ground as its treatment for a pair of rare bleeding disorders shows signs of efficacy, per Goldman Sachs.
Hemab Therapeutics is likely to gain ground as its treatment for a pair of rare bleeding disorders shows signs of efficacy, per Goldman Sachs.
